FDA Approved Boston Scientific’s Ranger Balloon
The Ranger Drug-Coated Balloon was approved today (10/2) by the U.S. Food and Drug Administration (FDA) for the treatment of patients with peripheral artery disease, a disease that affects 200 million people. The disease is characterized by a plaque build up in the...
Johnson & Johnson Informs CDC of Plans to Experiment Vaccine Candidate on 12-18-Year-olds
In late September, Johnson & Johnson commenced a clinical study for their COVID-19 vaccine candidate on 60,000 adults. A company executive declared that they would start experimenting as soon as possible, and depending on results, and other factors would continue...
Moderna’s Late Stage COVID-19 Vaccine on Track to Release Data Next Month
Today, (10/29) Moderna said that will release data on its experimental COVID-19 vaccine that will give insight on its efficacy. The company says they will produce 20 million doses by the end of the year. Pfizer and BioNTech are using similar technology to create their...
World Health Organization Backed by COVAX to Deliver 200 Million COVID-19 Vaccines
The COVAX initiative, worth $18 billion, is planning to administer COVID-19 vaccines to two-thirds of the world’s population by 2021. Sanofi and GalxoSmithKline have agreed to supply 2 million doses to the World Health Organization (WHO) of a vaccine they have been...
FDA Grants Clearance to Abiomed’s Launch of their Artificial Lung
Abiomed’s cardiopulmonary bypass system was cleared by the U.S. Food and Drug Administration (FDA) today (10/27) proceeding their April acquisition of Breethe. The effects of COVID-19 have created an increased need for heart recovery in cardiogenic shock patients....
Moderna Inc. Agrees with Qatar Ministry of Public Health for COVID-19 Vaccine Candidate
Today (10/26), Moderna, a top Biopharmaceutical employer, agreed to supply Qatar with their candidate COVID-19 vaccine, which has not yet been approved by any regulatory body. Moderna is currently scaling up their global manufacturing capabilities to be able to...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com